271. 強直性脊椎炎 Disease details / Clinical trials / Drug dev / DR info

0.9ML sodium chloride
   Chinese University of Hong Kong
      2010   Phase 4   NCT01212653   China
100 MG
   Department of Orthopedics, the First Affliated Hospital of Xinjiang Medical University
      2024   Phase 4   ChiCTR2400092488   China
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-002061-54-IT   Italy
150 MG double-blinded secukinumab
   Novartis Pharmaceuticals
      2018   Phase 4   NCT03350815   United States
150 MG OPEN-label secukinumab
   Novartis Pharmaceuticals
      2018   Phase 4   NCT03350815   United States
300 MG double-blinded secukinumab
   Novartis Pharmaceuticals
      2018   Phase 4   NCT03350815   United States
331731-18-1
   Abbott
      -   -   EUCTR2014-004532-18-Outside-EU/EEA   Japan
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Eli Lilly & Company
      2013   -   EUCTR2011-002325-22-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002325-22-GB   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   -   EUCTR2011-002325-22-ES   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   -   EUCTR2011-002325-22-DE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002325-22-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Faculdade de Ciências Médicas da Universidade Nova de Lisboa
      2014   Phase 4   EUCTR2013-004406-25-PT   Portugal
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
   Novartis Farmacéutica, S.A.
      2017   Phase 3   EUCTR2017-000679-10-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2019   Phase 3   EUCTR2017-000679-10-GR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-SK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-NL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-CZ   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-GB   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-FI   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
   Regionalhospital Silkeborg
      2010   Phase 4   EUCTR2009-018085-35-DK   Denmark
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland
   Samsung Bioepis Co., Ltd.
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
40 MG MSB11022
   Fresenius Kabi SwissBioSim GmbH
      2019   Phase 1   NCT04018599   United States
5-chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
608 dose A
   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
      2024   Phase 2   NCT06242652   China
608 dose B
   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
      2024   Phase 2   NCT06242652   China
608 dose C
   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
      2024   Phase 2   NCT06242652   China
99MTC-rhannexin V-128
   Advanced Accelerator Applications
      2014   Phase 1/Phase 2   NCT02328027   Switzerland
A simulated agent OF jitongning tablets
   Tasly Pharmaceutical Group Co., Ltd
      2023   Phase 3   NCT06000956   China
Abatacept
   Charite University, Berlin, Germany
      2008   Phase 2   NCT00558506   Germany
   Charité University Medicine
      2007   -   EUCTR2007-002967-28-DE   Germany
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
Abbvie care 2.0
   AbbVie
      2016   -   NCT02750800   Hungary
ABT-494
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2019-003229-12-IT   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 3   EUCTR2019-003229-12-SK   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-HU   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-GB   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-FR   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-ES   Argentina;Australia;Brazil;Canada;China;Hungary;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-DE   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-SE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-NL   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-HR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-DE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-PT   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-PL   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-HU   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-GB   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-FR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-FI   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-ES   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-DK   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-CZ   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-BE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
ABY-035
   Inmagene LLC
      2021   Phase 2   NCT04795141   Cayman Islands;China;Korea, Republic of;United States
Aclasta
   Cambridge University Hospitals NHS Foundation Trust
      2007   -   EUCTR2007-000087-25-GB   United Kingdom
Adalimumab
   ABBOTT
      2006   -   EUCTR2005-004826-21-IT   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
   AbbVie
      2016   -   NCT02750800   Hungary
      2014   -   NCT02333383   Korea, Republic of
      2013   -   NCT01768858   Austria
   Abbott
      2010   Phase 3   NCT01114880   China
      2008   Phase 3   NCT00667355   Japan
      2006   Phase 3   NCT00478660   Austria;Belgium;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom
      2004   Phase 3   NCT00085644   United States
      2003   Phase 3   NCT00195819   Canada;United States
      -   -   EUCTR2014-004532-18-Outside-EU/EEA   Japan
   Abbott GmbH & Co. KG
      2007   -   EUCTR2005-004826-21-BE   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-SE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-IE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-GR   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-GB   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-FI   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-ES   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-004826-21-DK   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-DE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-AT   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
   Abbott Japan Co., Ltd.
      2008   Phase 3   JPRN-jRCT2080220558   -
   Abbott Laboratories
      2006   -   EUCTR2005-004826-21-NO   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
   Celltrion HealthCare France
      2022   -   NCT05427942   France
   Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
      2008   -   EUCTR2007-003358-27-DE   Germany
   Chung Shan Medical University
      2008   Phase 4   NCT02489760   Taiwan
   Clinical Immunology and Rheumatology
      2009   -   EUCTR2008-006885-27-NL   Netherlands
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Eli Lilly & Company
      2013   -   EUCTR2011-002325-22-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002325-22-GB   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   -   EUCTR2011-002325-22-ES   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   -   EUCTR2011-002325-22-DE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002325-22-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
   Eli Lilly and Company
      2021   Phase 3   NCT04527380   Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2014   Phase 3   NCT01870284   Argentina;Belgium;Canada;Czech Republic;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Faculdade de Ciências Médicas da Universidade Nova de Lisboa
      2014   Phase 4   EUCTR2013-004406-25-PT   Portugal
   First Affiliated Hospital of Chengdu Medical College,Chengdu,China
      2023   Phase 4   ChiCTR2300072687   China
   Hvidovre University Hospital
      2004   Phase 4   NCT00133315   Denmark
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom
   Innovent Biologics (Suzhou) Co. Ltd.
      2016   Phase 3   NCT02893254   -
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland
   Jamp Pharma Corporation
      2023   -   NCT05913817   Canada
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
   Mianyang Hospital of Traditional Chinese Medicine
      2021   Phase 4   ChiCTR2100044045   China
   Novartis Farmacéutica, S.A.
      2017   Phase 3   EUCTR2017-000679-10-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2019   Phase 3   EUCTR2017-000679-10-GR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-SK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-NL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-CZ   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-GB   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-FI   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharma K.K.
      2018   Phase 3   JPRN-jRCT2080224045   Africa;Asia except Japan;Europe;Japan;North America;Oceania;South America
   Novartis Pharmaceuticals
      2017   Phase 3   NCT03259074   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
   READE
      2015   Phase 4   EUCTR2015-002284-42-FI   Finland
   Regionalhospital Silkeborg
      2010   Phase 4   EUCTR2009-018085-35-DK   Denmark
   Regionshospitalet Silkeborg
      2010   Phase 4   NCT01174186   Denmark
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland
   Samsung Bioepis Co., Ltd.
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
   Sichuan Provincial People's Hospital
      2024   Phase 4   ChiCTR2400081637   China
   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
      2024   Phase 2   NCT06242652   China
   The Affiliated Hospital Of Guizhou Medical University
      2025   Phase 4   NCT06833112   China
   The First Affiliated Hospital of Henan University of Chinese Medicine
      2023   -   ChiCTR2300071418   China
   Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
      2024   Phase 1   ChiCTR2400088487   China
      2023   Phase 4   ChiCTR2300071073   China
   Universidade Nova de Lisboa
      2015   Phase 4   NCT02492217   Portugal
   University Hospital, Tours
      2013   Phase 4   NCT01895764   France
   University of Sao Paulo
      2008   Phase 4   NCT01072058   Brazil
Adalimumab 40 MG SC every other week
   Charite University, Berlin, Germany
      2005   Phase 2/Phase 3   NCT00235105   Germany
Adalimumab AB
   Qilu Hospital of Shandong University
      2022   Phase 4   NCT05527444   China
Adalimumab and ITS biosimilars
   Hanyang University Seoul Hospital
      2022   Phase 4   NCT05164198   -
Adalimumab, etanercept, golimumab or infliximab
   University Hospital, Montpellier
      2012   -   NCT01610947   France
AIN457
   NOVARTIS FARMA
      2012   Phase 3   EUCTR2012-000046-35-IT   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2011   -   EUCTR2010-024529-18-IT   Belgium;Bulgaria;Canada;Germany;Italy;Mexico;Peru;Russian Federation;Taiwan;Turkey;United Kingdom
   NOVARTIS FARMA S.P.A.
      2015   Phase 3   EUCTR2013-005575-41-IT   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;United Kingdom
   Novartis Farma SpA
      2013   Phase 3   EUCTR2013-001089-40-IT   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2017   Phase 3   EUCTR2017-000679-10-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001090-24-ES   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-ES   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
   Novartis Pharma AG
      2021   Phase 4   EUCTR2020-004284-98-GR   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;United States
      2021   Phase 4   EUCTR2020-004284-98-BG   Belgium;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-SE   Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-IT   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-GR   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-CZ   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-BG   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-BE   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2019   Phase 3   EUCTR2017-000679-10-GR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-SK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-NL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-CZ   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-GB   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-FI   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      -   Phase 4   EUCTR2020-004284-98-PL   Belgium;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      -   Phase 4   EUCTR2020-004284-98-CZ   Brazil;Bulgaria;China;Colombia;Czech Republic;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Turkey;United States
   Novartis Pharma GmbH
      2016   Phase 4   EUCTR2015-004575-74-DE   Germany
   Novartis Pharma K.K.
      2016   Phase 3   JPRN-jRCT2080223186   -
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2015-005021-39-GB   China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom
      2016   Phase 3   EUCTR2015-005021-39-CZ   China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom
      2015   Phase 3   EUCTR2013-005575-41-SK   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-PL   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-NO   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-NL   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-GR   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-FI   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-DK   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-PT   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-NO   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-GR   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-GB   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-DE   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-BE   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001089-40-BG   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001089-40-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001090-24-CZ   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-NL   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-GB   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-NL   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-GB   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-FI   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-DE   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2011   -   EUCTR2010-024529-18-GB   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-024529-18-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-024529-18-BG   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-024529-18-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-011591-30-NL   Germany;Netherlands;United Kingdom;United States
      2010   Phase 2   EUCTR2009-011591-30-GB   Germany;Netherlands;United Kingdom
      2010   -   EUCTR2009-011591-30-DE   Germany;Netherlands;United Kingdom
      2009   -   EUCTR2008-002631-33-NL   Germany;Netherlands;United Kingdom
      2009   -   EUCTR2008-002631-33-GB   Germany;Netherlands;United Kingdom
      2008   -   EUCTR2008-002631-33-DE   Germany;Netherlands;United Kingdom
   Novartis Pharmaceuticals
      2016   Phase 4   NCT02763046   Germany
      2009   Phase 2   NCT00809159   Germany;Netherlands;United Kingdom;United States
AIN457 150 MG
   Novartis Pharmaceuticals
      2017   Phase 3   NCT03259074   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
AIN457, 150 MG
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2013-001089-40-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
AIN457, 75 MG
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2013-001089-40-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
AIN457A
   Novartis Pharmaceuticals
      2010   Phase 2   NCT01109940   Germany;Netherlands;United Kingdom;United States
AIN457F
   NOVARTIS FARMA
      2012   Phase 3   EUCTR2012-000046-35-IT   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
AK111
   Akeso
      2023   Phase 3   NCT06378697   China
      2021   Phase 2   NCT05467995   China
Alendronate
   Göteborg University
      2009   -   NCT01104987   Sweden
Anti TNF alpha agent
   All India Institute of Medical Sciences, New Delhi
      2011   -   NCT01361542   India
Anti TNF alpha therapy
   All India Institute of Medical Sciences, New Delhi
      2011   -   NCT01361542   India
ANTI-human interleukin-23 monoclonal antibody
   SUN Pharmaceuticals Global FZE
      2017   Phase 2   EUCTR2016-003936-19-HU   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003936-19-ES   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States
   Sun Pharma Global FZE
      2018   Phase 3   EUCTR2018-001060-35-ES   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States
   Sun Pharmaceutical Industries Limited (SPIL)
      2018   Phase 3   EUCTR2018-001060-35-HU   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States
ANTI-TNF
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-GB   Belgium;Finland;Germany;United Kingdom
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom
   University Hospital, Bordeaux
      2015   Phase 3   NCT02469753   France;Monaco
ANTI-TNF agents
   Istanbul Physical Medicine Rehabilitation Training and Research Hospital
      2019   -   NCT04943237   Turkey
ANTI-TNF therapy
   Imperial College London
      2010   -   NCT01060098   United Kingdom
ANTI-tumor necrosis factor
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      1999   Phase 2   NCT00000433   United States
Apremilast
   Celgene Corporation
      2013   Phase 3   EUCTR2011-001555-37-EE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-SK   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-SE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-PL   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-NL   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-FR   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
   Imperial College London
      2009   Phase 2   NCT00944658   United Kingdom
      2009   -   EUCTR2008-004229-40-GB   United Kingdom
Apremilast tablet 20 MG
   Amgen
      2012   Phase 3   NCT01583374   Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
Apremilast tablet 30 MG BID
   Amgen
      2012   Phase 3   NCT01583374   Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States
Arcoxia
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
Arcoxia 90 MG comprimidos recubiertos CON PELícula
   FUNDACIÓN ESPAÑOLA DE REUMATOLOGÍA (FER)
      2010   -   EUCTR2009-017309-12-ES   Spain
ARRY-371797
   Array BioPharma Inc.
      2009   -   EUCTR2008-007510-30-PL   Hungary;Poland
      2009   -   EUCTR2008-007510-30-HU   Hungary;Poland
ARRY-371797, P38 inhibitor
   Pfizer
      2008   Phase 2   NCT00811499   Canada;United States
Aspirin
   Department of Orthopedics, the First Affliated Hospital of Xinjiang Medical University
      2024   Phase 4   ChiCTR2400092488   China
Atorvastatin
   AMC
      2014   -   EUCTR2013-002860-19-NL   Netherlands
BAT1406
   Bio-Thera Solutions
      2016   Phase 3   NCT04135508   -
Bawei shenqi pill
   Shanghai University of Traditional Chinese Medicine
      2017   Phase 2/Phase 3   NCT04480359   China
BCD-055
   Biocad
      2016   Phase 3   NCT02762812   Russian Federation
      2015   Phase 1   NCT02359903   Belarus;Russian Federation
BCD-085
   Biocad
      2018   Phase 3   NCT03447704   Russian Federation
      2016   Phase 2   NCT02763111   -
Bdmard treatment
   Uppsala University
      2005   -   NCT02840695   -
Benepali
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
Benzathine penicillin
   Nanfang Hospital, Southern Medical University
      2025   Phase 4   NCT06707194   China
BI 655066 90 MG/ML
   Boehringer Ingelheim
      2014   Phase 2   EUCTR2013-003666-13-IT   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   Boehringer Ingelheim España, S.A.
      2013   Phase 2   EUCTR2013-003666-13-ES   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   Boehringer Ingelheim Finland Ky
      2013   Phase 2   EUCTR2013-003666-13-FI   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2014   Phase 2   EUCTR2013-003666-13-DE   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   Boehringer-Ingelheim bv
      2014   Phase 2   EUCTR2013-003666-13-NL   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   SCS Boehringer Ingelheim Comm.V
      2014   Phase 2   EUCTR2013-003666-13-BE   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
BI 730357
   Boehringer Ingelheim RCV GmbH & Co KG
      2020   Phase 2   EUCTR2019-001684-77-HU   Belgium;Czechia;Georgia;Germany;Hungary;Korea, Republic of;Moldova, Republic of;Romania;Spain;Ukraine;United States
Bifidobacterium
   Weihai Municipal Hospital of Shandong
      2018   -   ChiCTR1800017111   China
Bimekizumab
   UCB BIOPHARMA SRL
      2018   Phase 2   EUCTR2017-001002-15-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States
   UCB BIOSCIENCES GmbH
      2017   Phase 2   EUCTR2017-001002-15-HU   Hungary
   UCB Biopharma S.P.R.L.
      2017   Phase 2   NCT03215277   Australia;Czechia;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2016   Phase 2   NCT02963506   Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States
   UCB Biopharma SPRL
      2019   Phase 3   EUCTR2017-003065-95-FR   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-ES   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000957-37-NL   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-001002-15-ES   Germany;Hungary;Spain
      2017   Phase 2   EUCTR2017-000957-37-GR   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-DE   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-CZ   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2016-001102-42-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001102-42-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2017   Phase 2   EUCTR2016-001102-42-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2016   Phase 2   EUCTR2016-001102-42-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2016-001102-42-ES   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2016-001102-42-CZ   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
   UCB Biopharma SRL
      2025   Phase 3   NCT06668181   Canada;France;Germany;Poland;Spain;United Kingdom
      2020   Phase 3   NCT04436640   Belgium;Bulgaria;China;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-HU   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-GB   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-DE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-CZ   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-BG   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-BE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Türkiye;United Kingdom;United States
      2019   Phase 3   NCT03928743   Belgium;Bulgaria;China;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-NL   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-HU   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-GB   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-DE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-CZ   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-BG   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-BE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2017   Phase 2   NCT03355573   Bulgaria;Canada;Czechia;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States
      2017   Phase 2   EUCTR2017-001002-15-CZ   Bulgaria;Czech Republic;Germany;Hungary;Spain
      2017   Phase 2   EUCTR2017-001002-15-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States
   UCB Japan Co., Ltd
      2019   Phase 3   JPRN-jRCT2080224781   Asia except Japan;Japan;North America
   UCB Japan Co., Ltd.
      2020   Phase 3   JPRN-jRCT2080225318   Asia except Japan;Europe;Japan;North America
Biologic or targeted synthetic dmard
   Seoul National University Hospital
      2012   -   NCT01965132   Korea, Republic of
Biological: etanercept and ITS biosimilars
   Hanyang University Seoul Hospital
      2022   Phase 4   NCT05164198   -
Biosimilar
   Jamp Pharma Corporation
      2023   -   NCT05913817   Canada
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2018   -   NCT03729674   Canada
   Novartis Pharma K.K.
      2018   Phase 3   JPRN-jRCT2080224045   Africa;Asia except Japan;Europe;Japan;North America;Oceania;South America
   Novartis Pharmaceuticals
      2017   Phase 3   NCT03259074   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
   Opal Rheumatology Ltd.
      2018   -   NCT03470688   Australia
Blood collection
   CHU de Reims
      2015   -   NCT02809300   France
Blood samples
   Assistance Publique Hopitaux De Marseille
      2017   -   NCT03322618   France
Blood sampling from infant
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States
Blood sampling from mother
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States
Blood sampling from umbilical cord
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States
BMS-188667
   Charité University Medicine
      2007   -   EUCTR2007-002967-28-DE   Germany
BMS-986251
   Bristol-Myers Squibb
      2017   Phase 1/Phase 2   NCT03329885   Netherlands
Breast milk sampling
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02154425   France;Netherlands;Switzerland;United States
CA2
   Rheumazentrum Ruhrgebiet.
      2006   -   EUCTR2005-002460-29-FI   Belgium;Finland;Germany;United Kingdom
      2006   Phase 4   EUCTR2005-002460-29-BE   Belgium;Finland;Germany;United Kingdom
      2005   Phase 4   EUCTR2005-002460-29-GB   Belgium;Finland;Germany;United Kingdom
      2005   -   EUCTR2005-002460-29-DE   Belgium;Finland;Germany;United Kingdom
Calcium
   Department of Clinic Genetics, Changzheng Hospital, Naval Medical University
      2024   Phase 0   ChiCTR2400089135   China
Cannabidiol tablet 10 MG
   King Christian 10th Hospital for Rheumatology
      2018   Phase 2   EUCTR2017-004226-15-DK   Denmark
Cannabis questionnaire
   University Hospital, Clermont-Ferrand
      2020   -   NCT04402554   France
CC-10004
   Celgene Corporation
      2013   Phase 3   EUCTR2011-001555-37-EE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-SK   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-SE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-PL   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-NL   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-HU   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-FR   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-001555-37-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States
   Imperial College London
      2009   -   EUCTR2008-004229-40-GB   United Kingdom
CC-99677
   Celgene
      2021   Phase 2   NCT04947579   Canada;China;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States
CC-99677 30MG capsule
   Celgene Corporation
      2022   Phase 2   EUCTR2019-004108-37-RO   Canada;Czech Republic;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004108-37-PL   Canada;Czech Republic;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States
      2021   Phase 2   EUCTR2019-004108-37-DE   Canada;Czech Republic;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States
      2021   Phase 2   EUCTR2019-004108-37-CZ   Canada;Czech Republic;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States
CC-99677 60MG capsule
   Celgene Corporation
      2022   Phase 2   EUCTR2019-004108-37-RO   Canada;Czech Republic;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States
      2021   Phase 2   EUCTR2019-004108-37-PL   Canada;Czech Republic;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States
      2021   Phase 2   EUCTR2019-004108-37-DE   Canada;Czech Republic;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States
      2021   Phase 2   EUCTR2019-004108-37-CZ   Canada;Czech Republic;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States
CDP870
   SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
      2010   Phase 3   EUCTR2009-011719-19-GB   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2009-011719-19-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
   UCB BIOSCIENCES GmbH
      2016   Phase 3   EUCTR2015-001894-41-BG   Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States
      2015   Phase 3   EUCTR2015-001894-41-HU   Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States
      2015   Phase 3   EUCTR2015-001894-41-CZ   Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States
   UCB BioSciences GmbH
      2010   -   EUCTR2009-011719-19-NL   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2009-011719-19-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States
      2010   -   EUCTR2009-011719-19-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States
      2010   -   EUCTR2009-011719-19-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2009-011719-19-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States
   UCB Biopharma SPRL
      2018   Phase 2   EUCTR2017-000957-37-NL   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-GR   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-DE   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-CZ   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
Celebrex
   Charite Universitaetsmedizin
      2016   Phase 4   EUCTR2016-000615-33-DE   Germany
   Sun Yat-sen University
      2012   -   NCT01709656   China
Celecoxib
   Affiliated Hospital of Nanjing University of Chinese Medicine
      2021   Phase 0   ChiCTR2100044284   China
   Charite University, Berlin, Germany
      2016   Phase 4   NCT02758782   Germany
   China-Japan Friendship Hospital
      2021   Phase 0   ChiCTR2100052323   China
   Columbia University
      2018   Phase 4   NCT03473665   United States
   Guangdong Provincial Hospital of Chinese Medicine
      2021   Phase 0   ChiCTR2100042789   China
      2007   Phase 1 study   ChiCTR-TRC-13004564   China
   Jiangsu Province Hospital of TCM
      2019   -   ChiCTR2000034142   China
   Pfizer
      2003   Phase 3   NCT00648141   Germany
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2009   Phase 3   NCT00762463   China
   Southwest Hospital, China
      2024   -   NCT05960864   -
   Sun Yat-sen University
      2012   -   NCT01709656   China
   The First Affiliated Hospital of Henan University of Chinese Medicine
      2023   -   ChiCTR2300067535   China
   Zhixiang Huang
      2016   Phase 4   NCT02638896   -
Celecoxib 200 milligrams
   Pfizer
      2002   Phase 4   NCT02528201   Norway
Celecoxib 400 milligrams
   Pfizer
      2002   Phase 4   NCT02528201   Norway
Certolizumab
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland
Certolizumab pegol
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
   READE
      2015   Phase 4   EUCTR2015-002284-42-FI   Finland
   SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
      2010   Phase 3   EUCTR2009-011719-19-GB   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2009-011719-19-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
   UCB BIOSCIENCES GmbH
      2015   Phase 3   NCT02505542   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Hungary;Netherlands;Poland;Romania;Spain;Taiwan;Turkey;United Kingdom;United States
   UCB BIOSCIENCES, Inc.
      2014   Phase 1   NCT02154425   France;Netherlands;Switzerland;United States
      2014   Phase 1   NCT02019602   France;Netherlands;Switzerland;United States
   UCB BioSciences GmbH
      2010   -   EUCTR2009-011719-19-NL   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2009-011719-19-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States
      2010   -   EUCTR2009-011719-19-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States
      2010   -   EUCTR2009-011719-19-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2009-011719-19-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States
   UCB Biopharma S.P.R.L.
      2017   Phase 2   NCT03215277   Australia;Czechia;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
   UCB Biopharma SPRL
      2018   Phase 2   EUCTR2017-000957-37-NL   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-GR   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-DE   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-CZ   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
Certolizumab pegol / cimzia
   UCB Biosciences Inc.
      2014   Phase 1   EUCTR2013-003812-30-NL   France;Germany;Netherlands;Switzerland;United States
Cimzia
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
   READE
      2015   Phase 4   EUCTR2015-002284-42-FI   Finland
   SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
      2010   Phase 3   EUCTR2009-011719-19-GB   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2009-011719-19-FR   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
   UCB BioSciences GmbH
      2010   -   EUCTR2009-011719-19-NL   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2009-011719-19-HU   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States
      2010   -   EUCTR2009-011719-19-DE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States
      2010   -   EUCTR2009-011719-19-CZ   Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2009-011719-19-BE   Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States
Cimzia 200 MG solution FOR injection
   UCB Biopharma SPRL
      2018   Phase 2   EUCTR2017-000957-37-NL   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-GR   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-DE   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-CZ   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
Cimzia certolizumab pegol 200 MG/ML solution FOR injection
   UCB BIOSCIENCES GmbH
      2016   Phase 3   EUCTR2015-001894-41-BG   Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States
      2015   Phase 3   EUCTR2015-001894-41-HU   Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States
      2015   Phase 3   EUCTR2015-001894-41-CZ   Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States
Cnto 148
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-GB   Belgium;Finland;Germany;United Kingdom
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom
   Centocor, Inc.
      2005   Phase 3   NCT00265083   Belgium;Canada;Finland;France;Germany;Korea, Republic of;Netherlands;Taiwan;United Kingdom;United States
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom
Comparative efficacy and safety OF thalidomide and sulfasalazine IN moderate TO severe ankylosing spondylitis: A REAL-world study from bangladesh
   Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
      2017   Phase 3   NCT06985134   Bangladesh
Conventional therapy users FOR THE last 5 years
   Istanbul Physical Medicine Rehabilitation Training and Research Hospital
      2019   -   NCT04943237   Turkey
Cosentyx
   Afdeling for Rygkirurgi, Led- og Bindevævssygdomme ; Rigshospitalet - Glostrup
      2018   Phase 4   EUCTR2017-004037-93-DK   Denmark
   Novartis Farmacéutica, S.A.
      2017   Phase 3   EUCTR2017-000679-10-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2021   Phase 4   EUCTR2020-004284-98-GR   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;United States
      2021   Phase 4   EUCTR2020-004284-98-BG   Belgium;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      2019   Phase 3   EUCTR2017-000679-10-GR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-SK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-NL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-CZ   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-GB   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-FI   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      -   Phase 4   EUCTR2020-004284-98-PL   Belgium;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      -   Phase 4   EUCTR2020-004284-98-CZ   Brazil;Bulgaria;China;Colombia;Czech Republic;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Turkey;United States
   Novartis Pharma GmbH
      2016   Phase 4   EUCTR2015-004575-74-DE   Germany
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2015-005021-39-GB   China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom
      2016   Phase 3   EUCTR2015-005021-39-CZ   China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom
      2015   Phase 3   EUCTR2013-005575-41-PL   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001089-40-BG   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001089-40-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001090-24-CZ   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-NL   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-GB   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-NL   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-GB   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-FI   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-DE   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
   Professor Mikkel Østergaard
      2019   Phase 4   NCT03639740   Denmark
CP-690,550-10
   Pfizer Inc, 235 East 42nd Street, New York 10017
      2013   -   EUCTR2011-005689-39-HU   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States
   Pfizer Inc.
      2018   Phase 3   EUCTR2018-000226-58-CZ   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2014   Phase 2   EUCTR2011-005689-39-SK   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States
      2014   Phase 2   EUCTR2011-005689-39-NL   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States
      2014   -   EUCTR2011-005689-39-DE   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States
      2013   Phase 2   EUCTR2011-005689-39-ES   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States
      2013   -   EUCTR2011-005689-39-CZ   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 3   EUCTR2018-000226-58-HU   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-GB   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-FR   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-ES   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-DE   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-BG   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-AT   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
CT-P13
   Pfizer
      2015   -   NCT02605642   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Spain;United Kingdom
CTLA4IG
   Charité University Medicine
      2007   -   EUCTR2007-002967-28-DE   Germany
Diclofenac
   Chinese PLA General Hospital
      2010   Phase 1 study   ChiCTR-ONRC-10000858   China
   Columbia University
      2018   Phase 4   NCT03473665   United States
   Johnson & Johnson Taiwan Ltd
      2008   Phase 4   NCT00766402   -
   Pfizer
      2003   Phase 3   NCT00648141   Germany
Diclofenac 50 milligrams
   Pfizer
      2002   Phase 4   NCT02528201   Norway
Diclofenac SR
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2009   Phase 3   NCT00762463   China
Diclophenac
   Charite University, Berlin, Germany
      2008   Phase 4   NCT00715091   Germany
Dmards
   Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
      2009   -   ChiCTR-ONRC-11001846   -
   Janssen Research & Development, LLC
      2015   -   NCT02293681   China
Dronabinol capsule 2.5. MG
   King Christian 10th Hospital for Rheumatology
      2018   Phase 2   EUCTR2017-004226-15-DK   Denmark
E-device
   UCB Biopharma S.P.R.L.
      2017   Phase 3   NCT03357471   United States
Enbrel
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
   Norfolk & Norwich University Hospitals NHS Foundation Trust
      2010   Phase 4   EUCTR2010-020913-10-GB   United Kingdom
   Pfizer
      2011   -   NCT01411215   China
      2009   -   NCT01421303   Belgium
      2008   -   NCT01188655   -
   READE
      2015   Phase 4   EUCTR2015-002284-42-FI   Finland
   Samsung Bioepis Co., Ltd.
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
   WYETH LEDERLE
      2009   -   EUCTR2007-003096-39-IT   Italy
      2006   -   EUCTR2005-001549-41-IT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
   Wyeth Farma S.A.
      2006   Phase 4   EUCTR2006-002349-35-ES   Spain
   Wyeth Pharmaceuticals B.V.
      2009   -   EUCTR2009-015515-40-NL   Netherlands
   Wyeth Pharmaceuticals France
      2008   -   EUCTR2006-002748-27-HU   France;Germany;Hungary;Netherlands
      2007   -   EUCTR2006-002748-27-NL   France;Germany;Hungary;Netherlands
      2007   -   EUCTR2006-002748-27-DE   France;Germany;Hungary;Netherlands
      2006   Phase 4   EUCTR2006-002748-27-FR   France;Germany;Hungary;Netherlands
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 3   NCT00434044   -
      2007   Phase 4   NCT00420238   France;Germany;Hungary;Netherlands
      2006   Phase 4   NCT00410046   Denmark;Finland;Sweden;United Kingdom
      2004   Phase 4   NCT00444340   -
      2002   Phase 3   NCT00421915   -
Enbrel plus celebrex
   Sun Yat-sen University
      2014   Phase 4   NCT01934933   China
ENIA11
   Mycenax Biotech Inc.
      2016   Phase 3   NCT02685904   Taiwan
Entecavir
   Seoul National University Hospital
      2012   Phase 3   NCT01694264   Korea, Republic of
Etanercept
   Amgen
      2002   Phase 3   NCT00356356   United States
   AryoGen Pharmed Co.
      2014   -   NCT04582084   Iran, Islamic Republic of
   Charite University, Berlin, Germany
      2002   Phase 2   NCT01289743   Germany
   Chung Shan Medical University
      2008   Phase 4   NCT02489760   Taiwan
   Hvidovre University Hospital
      2004   Phase 4   NCT00133315   Denmark
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
   Nanfang Hospital of Southern Medical University
      2019   Phase 4   NCT04077957   China
      2019   -   ChiCTR1900025749   China
   Nanfang Hospital, Southern Medical University
      2025   Phase 4   NCT06707194   China
   Norfolk & Norwich University Hospitals NHS Foundation Trust
      2010   Phase 4   EUCTR2010-020913-10-GB   United Kingdom
   Pfizer
      2020   -   NCT04507763   Iraq
      2014   -   NCT02202850   Belgium
      2010   -   NCT01793285   Spain
      2009   Phase 4   NCT00910273   Italy
      2007   -   NCT00544557   Germany
   READE
      2015   Phase 4   EUCTR2015-002284-42-FI   Finland
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2016   Phase 2/Phase 3   NCT02809781   China
   Sun Yat-sen University
      2007   Phase 4   NCT02915354   China
   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
      2014   Phase 3   NCT04345458   China
   University of Sao Paulo
      2008   Phase 4   NCT01072058   Brazil
   University of Sulaimani
      2022   -   NCT05379049   Iraq
   WYETH LEDERLE
      2009   -   EUCTR2007-003096-39-IT   Italy
      2006   -   EUCTR2005-001549-41-IT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
   West China Hospital of Sichuan University
      2022   -   ChiCTR2100054201   China
   Wyeth Farma S.A.
      2006   Phase 4   EUCTR2006-002349-35-ES   Spain
   Wyeth Pharmaceuticals France
      2008   -   EUCTR2006-002748-27-HU   France;Germany;Hungary;Netherlands
      2007   -   EUCTR2006-002748-27-NL   France;Germany;Hungary;Netherlands
      2007   -   EUCTR2006-002748-27-DE   France;Germany;Hungary;Netherlands
      2006   Phase 4   EUCTR2006-002748-27-FR   France;Germany;Hungary;Netherlands
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2007   -   EUCTR2006-001061-42-FI   Denmark;Finland;Sweden;United Kingdom
      2006   -   EUCTR2006-001061-42-SE   Denmark;Finland;Sweden;United Kingdom
      2006   Phase 4   EUCTR2006-001061-42-GB   Denmark;Finland;Sweden;United Kingdom
      2006   -   EUCTR2006-001061-42-DK   Denmark;Finland;Sweden;United Kingdom
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 3   NCT00434044   -
      2007   Phase 4   NCT00420238   France;Germany;Hungary;Netherlands
      2006   Phase 4   NCT00873730   -
      2006   Phase 4   NCT00458185   -
      2006   Phase 4   NCT00410046   Denmark;Finland;Sweden;United Kingdom
      2005   Phase 4   NCT00247962   Australia;Austria;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Qatar;Saudi Arabia;Spain;Sweden;Switzerland;United Kingdom
      2005   -   NCT00195416   Korea, Republic of
      2004   Phase 4   NCT00444340   -
      2004   Phase 3   NCT00418548   -
      2002   Phase 3   NCT00421980   Belgium
      2002   Phase 3   NCT00421915   -
   Zhixiang Huang
      2016   Phase 4   NCT02638896   -
Etanercept biosimilar
   Samsung Bioepis Co., Ltd.
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
Etanercept or adalimumab
   Imperial College London
      2010   -   NCT01060098   United Kingdom
Etoricoxib
   FUNDACIÓN ESPAÑOLA DE REUMATOLOGÍA (FER)
      2010   -   EUCTR2009-017309-12-ES   Spain
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
   Organon and Co
      2011   -   NCT01327638   -
      2009   -   NCT01077843   -
      2006   -   NCT01685424   United States
   Spanish Foundation of Rheumatology
      2010   Phase 3   NCT01091675   Spain
Eupatilin
   Seoul National University Boramae Hospital
      2021   Phase 4   NCT04885751   -
Faecal microbiota transplantation
   Odense University Hospital
      2023   Phase 2   NCT04924270   Denmark
Fecal microbiota transplantation
   Hospital District of Helsinki and Uusimaa
      2018   Early Phase 1   NCT03726645   Finland
   The First Medical Center of Chinese PLA General Hospital
      2021   Phase 0   ChiCTR2100046200   China
Fengshigutong capsule plus imrecoxib
   Sun Yat-sen University
      2016   Phase 4   NCT03932006   China
Filgotinib
   Galapagos NV
      2019   Phase 2   EUCTR2018-003933-14-LV   Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine
      2019   Phase 2   EUCTR2018-003933-14-ES   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine
      2019   Phase 2   EUCTR2018-003933-14-EE   Belgium;Bulgaria;Czech Republic;Czechia;Estonia;Latvia;Poland;Spain;Ukraine
      2019   Phase 2   EUCTR2018-003933-14-CZ   Belgium;Bulgaria;Czech Republic;Czechia;Estonia;Latvia;Poland;Spain;Ukraine
      2019   Phase 2   EUCTR2018-003933-14-BG   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Czechia;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine
      2019   Phase 2   EUCTR2018-003933-14-BE   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine
      2017   Phase 2   NCT03117270   Belgium;Bulgaria;Czechia;Estonia;Poland;Spain;Ukraine
      2017   Phase 2   EUCTR2016-003636-21-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine
      2017   Phase 2   EUCTR2016-003636-21-EE   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine
      2017   Phase 2   EUCTR2016-003636-21-CZ   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine
      2017   Phase 2   EUCTR2016-003636-21-BG   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine
      2017   Phase 2   EUCTR2016-003636-21-BE   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine
   Gilead Sciences
      2020   Phase 3   NCT04483700   -
      2020   Phase 3   NCT04483687   -
FMT
   University Hospital of North Norway
      2024   Phase 2   NCT06451588   Norway
Focetria
   Tel-Aviv Sourasky Medical Center
      2009   Phase 2   NCT01006681   -
General population
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States
Ginger
   Affiliated Hospital of Nanjing University of Chinese Medicine
      2021   Phase 0   ChiCTR2100044284   China
GLPG0634
   Galapagos NV
      2019   Phase 2   EUCTR2018-003933-14-LV   Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine
      2019   Phase 2   EUCTR2018-003933-14-ES   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine
      2019   Phase 2   EUCTR2018-003933-14-EE   Belgium;Bulgaria;Czech Republic;Czechia;Estonia;Latvia;Poland;Spain;Ukraine
      2019   Phase 2   EUCTR2018-003933-14-CZ   Belgium;Bulgaria;Czech Republic;Czechia;Estonia;Latvia;Poland;Spain;Ukraine
      2019   Phase 2   EUCTR2018-003933-14-BG   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Czechia;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine
      2019   Phase 2   EUCTR2018-003933-14-BE   Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine
      2017   Phase 2   EUCTR2016-003636-21-ES   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine
      2017   Phase 2   EUCTR2016-003636-21-EE   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine
      2017   Phase 2   EUCTR2016-003636-21-CZ   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine
      2017   Phase 2   EUCTR2016-003636-21-BG   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine
      2017   Phase 2   EUCTR2016-003636-21-BE   Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine
Golimumab
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-GB   Belgium;Finland;Germany;United Kingdom
   Centocor, Inc.
      2010   Phase 3   NCT01248793   China
      2005   Phase 3   NCT00265083   Belgium;Canada;Finland;France;Germany;Korea, Republic of;Netherlands;Taiwan;United Kingdom;United States
   Charite University, Berlin, Germany
      2016   Phase 4   NCT02758782   Germany
   Hanyang University Seoul Hospital
      2022   Phase 4   NCT05164198   -
   Janssen Biologics, BV
      2014   Phase 3   EUCTR2014-000241-74-DE   Australia;Brazil;Canada;Germany;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Ukraine;United States
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States
   Janssen Research & Development, LLC
      2014   Phase 3   NCT02186873   Australia;Brazil;Canada;Germany;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Ukraine;United States
   Johnson & Johnson Private Limited
      2019   Phase 4   NCT03733925   India
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
   MERCK SHARP & DOHME B.V.
      2012   Phase 4   EUCTR2012-002458-21-NL   Netherlands
   Merck Sharp & Dohme Corp.
      2012   Phase 4   NCT01668004   Netherlands
   READE
      2015   Phase 4   EUCTR2015-002284-42-FI   Finland
Golimumab injection
   MSD Pharmaceuticals LLC
      2016   -   NCT03557853   Russian Federation
Golimumab liquid IN vial
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom
Golimumab PRE-filled syringe
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom
GP2017
   Novartis Farmacéutica, S.A.
      2017   Phase 3   EUCTR2017-000679-10-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharma AG
      2019   Phase 3   EUCTR2017-000679-10-GR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-SK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-NL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-CZ   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-GB   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-FI   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharma K.K.
      2018   Phase 3   JPRN-jRCT2080224045   Africa;Asia except Japan;Europe;Japan;North America;Oceania;South America
   Novartis Pharmaceuticals
      2017   Phase 3   NCT03259074   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
Hemay005
   Tianjin Hemay Pharmaceutical Co., Ltd
      2022   Phase 2   NCT05407246   China
Herpes zoster vaccine
   University of Alabama at Birmingham
      2016   Phase 2   NCT02538341   United States
      2013   Phase 2   NCT02538757   United States
Human ANTI-tnfa monoclonal antibody
   Janssen Biologics, BV
      2014   Phase 3   EUCTR2014-000241-74-DE   Australia;Brazil;Canada;Germany;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Ukraine;United States
Human ANTI-tnfalfa
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-GB   Belgium;Finland;Germany;United Kingdom
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom
Human umbilical cord mesenchymal stem cells
   Asia Cell Therapeutics (Shanghai) Co., Ltd.
      2023   Phase 1   NCT05962762   -
Human umbilical CORD-derived mscs
   Shandong University
      2011   Phase 1   NCT01420432   China
Humira
   Abbott
      2006   Phase 3   NCT00478660   Austria;Belgium;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom
   Abbott GmbH & Co. KG
      2007   -   EUCTR2005-004826-21-BE   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-SE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-IE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-GR   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-GB   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-FI   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-ES   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-004826-21-DK   Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-DE   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004826-21-AT   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
   Abbott Laboratories
      2006   -   EUCTR2005-004826-21-NO   Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom
   Bio-Thera Solutions
      2016   Phase 3   NCT04135508   -
   Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
      2008   -   EUCTR2007-003358-27-DE   Germany
   Clinical Immunology and Rheumatology
      2009   -   EUCTR2008-006885-27-NL   Netherlands
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Faculdade de Ciências Médicas da Universidade Nova de Lisboa
      2014   Phase 4   EUCTR2013-004406-25-PT   Portugal
   Imperial College London South Kensington London
      2009   Phase 4   EUCTR2009-012424-87-GB   United Kingdom
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
   READE
      2015   Phase 4   EUCTR2015-002284-42-FI   Finland
   Regionalhospital Silkeborg
      2010   Phase 4   EUCTR2009-018085-35-DK   Denmark
   Samsung Bioepis Co., Ltd.
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
Humira 40 MG/0.8 ML solution FOR injection
   Abbott
      -   -   EUCTR2014-004532-18-Outside-EU/EEA   Japan
Hydroxychloroquine
   Nanfang Hospital of Southern Medical University
      2019   Phase 4   NCT04077957   China
Hyrimoz
   Novartis Pharma AG
      2019   Phase 3   EUCTR2017-000679-10-GR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-SK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-NL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-CZ   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-FI   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
IBI303
   Innovent Biologics (Suzhou) Co. Ltd.
      2016   Phase 3   NCT02893254   -
Ibuprofen
   School of Chinese Medicine Southern Medical University
      2010   -   ChiCTR-TRC-11001274   China
Iguratimod
   PLA General Hospital
      2018   -   ChiCTR1800019227   China
   Qilu Hospital of Shandong University
      2021   Phase 4   ChiCTR2100043171   China
Ilumetri
   Sun Pharmaceutical Industries Limited (SPIL)
      2018   Phase 3   EUCTR2018-001060-35-HU   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States
Indomethacin
   Boehringer Ingelheim
      2001   Phase 3   NCT02183168   -
   Columbia University
      2018   Phase 4   NCT03473665   United States
   Sun Yat-sen Memorial Hospital of Sun Yat-sen University
      2011   Phase 1+Phase 2   ChiCTR-TRC-11001417   China
Infliximab
   Association de Recherche Clinique en Rhumatologie
      2003   Phase 3   NCT00439283   France
   Biocad
      2015   Phase 1   NCT02359903   Belarus;Russian Federation
   CHRU-TOURS
      2007   -   EUCTR2006-005157-29-FR   France
   Celltrion
      2012   Phase 1   NCT01571206   Korea, Republic of
      2010   Phase 1   NCT01220518   Korea, Republic of
   Centocor, Inc.
      2002   Phase 3   NCT00207701   -
   Gu Jieruo
      2008   Phase 4   NCT00936143   China
   Göteborg University
      2003   -   NCT01850121   Sweden
   Hvidovre University Hospital
      2004   Phase 4   NCT00133315   Denmark
   Jagiellonian University
      2013   Phase 4   NCT02132234   Poland
   Janssen Korea, Ltd., Korea
      2007   -   NCT00760669   Korea, Republic of
      2007   -   NCT00724529   Korea, Republic of
   Janssen Research & Development, LLC
      2015   -   NCT02293681   China
   Merck Sharp & Dohme Corp.
      2010   Phase 4   NCT01148901   Spain
      2009   Phase 3   NCT00844805   Austria;Belgium;Denmark;France;Germany;Hungary;Korea, Republic of;Russian Federation;Ukraine;United States
      2005   Phase 3   NCT00202865   Canada
      2004   Phase 4   NCT00779012   -
      2004   -   NCT00725543   -
      2003   -   NCT00818168   Germany
   Mitsubishi Tanabe Pharma Corporation
      2007   Phase 3   JPRN-jRCT2080220341   -
   READE
      2015   Phase 4   EUCTR2015-002284-42-FI   Finland
   Rheumazentrum Ruhrgebiet
      2005   -   NCT00237419   Belgium;Finland;France;Germany;Netherlands;United Kingdom
   Rheumazentrum Ruhrgebiet.
      2006   -   EUCTR2005-002460-29-FI   Belgium;Finland;Germany;United Kingdom
      2006   Phase 4   EUCTR2005-002460-29-BE   Belgium;Finland;Germany;United Kingdom
      2005   Phase 4   EUCTR2005-002460-29-GB   Belgium;Finland;Germany;United Kingdom
      2005   -   EUCTR2005-002460-29-DE   Belgium;Finland;Germany;United Kingdom
   Schering Plough, S.A
      2010   -   EUCTR2009-016587-36-ES   Spain
   Schering-Plough France
      2008   -   EUCTR2006-001579-40-DK   Denmark;France;Hungary;Spain
      2007   Phase 4   EUCTR2006-001579-40-HU   Denmark;France;Hungary;Spain
      2007   Phase 4   EUCTR2006-001579-40-FR   Denmark;France;Hungary;Spain
      2007   -   EUCTR2006-001579-40-ES   Denmark;France;Hungary;Spain
   University Hospital, Tours
      2007   Phase 4   NCT00507403   France
   University of Sao Paulo
      2008   Phase 4   NCT01072058   Brazil
Infliximab and MTX
   Chinese University of Hong Kong
      2005   Phase 4   NCT00432432   -
Infliximab biosimilar
   Hanyang University Seoul Hospital
      2022   Phase 4   NCT05164198   -
Infliximab infusion
   Chiba University Hospital
      2012   Phase 2   JPRN-UMIN000015297   Japan
      2012   Phase 2   JPRN-UMIN000007806   Japan
Infliximab: adalimumab
   University of Sulaimani
      2022   -   NCT05379049   Iraq
Interleukin 2
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 2   NCT01988506   France
Intravenous infusion OF mscs
   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      2016   Phase 2/Phase 3   NCT02809781   China
Ixekizumab
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Eli Lilly & Company
      2013   -   EUCTR2011-002325-22-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002325-22-GB   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   -   EUCTR2011-002325-22-ES   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   -   EUCTR2011-002325-22-DE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002325-22-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
   Eli Lilly and Company
      2021   Phase 3   NCT04527380   Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2014   Phase 3   NCT01870284   Argentina;Belgium;Canada;Czech Republic;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
Jaktinib
   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
      2023   Phase 3   NCT05861128   China
      2023   Phase 3   NCT05861102   China
Jaktinib hydrochloride tablets
   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
      2020   Phase 2   NCT04507659   China
Jing SI herbal TEA liquid packets
   Buddhist Tzu Chi General Hospital
      2022   -   NCT05257174   Taiwan
JS005
   Shanghai Junshi Bioscience Co., Ltd.
      2024   Phase 2   NCT06250062   China
      2021   Phase 2   NCT05212051   China
KIN-1901
   Kinevant Sciences GmbH
      2019   Phase 1   NCT04205851   Canada
Kunxian capsule
   Gu Jieruo
      2008   Phase 4   NCT00953979   China
L04aa24
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
L04ab0
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
L04ab01
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
L04ab04
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
L04ab05
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
Laboratory testing
   Oregon Health and Science University
      2021   Early Phase 1   NCT05119712   United States
Leflunomide
   The First Affiliated Hospital of Heilongjiang Chinese Medicine Colledge
      2018   -   ChiCTR-INR-17013574   China
LNK01001
   Lynk Pharmaceuticals Co., Ltd
      2022   Phase 2   NCT06085534   China
Loxoprofen sodium hydrogel patch
   Sun Yat-sen University
      2015   Phase 4   NCT03800797   China
Loxoprofen sodium tablet
   Sun Yat-sen University
      2015   Phase 4   NCT03800797   China
LY2439821
   Eli Lilly & Company
      2013   -   EUCTR2011-002325-22-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002325-22-GB   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   -   EUCTR2011-002325-22-ES   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   -   EUCTR2011-002325-22-DE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002325-22-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
Mabthera 500
   University Hospital of North Staffordshire
      2006   Phase 2   EUCTR2005-005358-27-GB   United Kingdom
Meloxicam
   Columbia University
      2018   Phase 4   NCT03473665   United States
   Shanghai University of Traditional Chinese Medicine
      2017   Phase 2/Phase 3   NCT04480359   China
   Zhejiang University of Traditional Chinese Medicine
      2021   -   ChiCTR2100048756   China
Meloxicam suppository
   Boehringer Ingelheim
      2001   Phase 3   NCT02183168   -
Meloxicam tablet
   Boehringer Ingelheim
      2001   Phase 3   NCT02183168   -
Mesenchymal stem cells
   National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
      2025   Phase 1/Phase 2   NCT06888973   Pakistan
Methotrexate
   Association de Recherche Clinique en Rhumatologie
      2003   Phase 3   NCT00439283   France
   CHRU-TOURS
      2007   -   EUCTR2006-005157-29-FR   France
   Charite University, Berlin, Germany
      2003   Phase 2   NCT00243750   Germany
   Janssen Korea, Ltd., Korea
      2007   -   NCT00760669   Korea, Republic of
   Merck Sharp & Dohme Corp.
      2010   -   NCT01313858   Germany
   Nanfang Hospital of Southern Medical University
      2019   Phase 4   NCT04077957   China
   University Hospital, Tours
      2013   Phase 4   NCT01895764   France
Methotrexate disodium
   CHRU de TOURS
      2013   Phase 4   EUCTR2012-004939-23-FR   France
Methylprednisolone
   Saratov State Medical University
      2012   Phase 2   NCT01790022   Russian Federation
Metoject
   CHRU de TOURS
      2013   Phase 4   EUCTR2012-004939-23-FR   France
Misoprostol
   Korea Otsuka Pharmaceutical Co.,Ltd.
      2007   Phase 3   NCT00576706   Korea, Republic of
MK-0663
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
MK-3222
   SUN Pharmaceuticals Global FZE
      2017   Phase 2   EUCTR2016-003936-19-HU   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003936-19-ES   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States
   Sun Pharma Global FZE
      2018   Phase 3   EUCTR2018-001060-35-ES   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States
   Sun Pharmaceutical Industries Limited (SPIL)
      2018   Phase 3   EUCTR2018-001060-35-HU   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States
Mrna COVD19 vaccine
   Mayo Clinic
      2021   Early Phase 1   NCT04839315   United States
MSC
   Sun Yat-sen Memorial Hospital of Sun Yat-sen University
      2011   Phase 1+Phase 2   ChiCTR-TRC-11001417   China
   Sun Yat-sen University
      2012   -   NCT01709656   China
Méthotrexate
   CHRU-TOURS
      2007   -   EUCTR2006-005157-29-FR   France
Nanocurcumin
   Tabriz University of Medical Sciences
      2017   Phase 2   NCT03140657   Iran, Islamic Republic of
Naprosyn
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
Naprosysn
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
Naproxen
   Merck Sharp & Dohme Corp.
      2009   Phase 3   NCT00844805   Austria;Belgium;Denmark;France;Germany;Hungary;Korea, Republic of;Russian Federation;Ukraine;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
   POZEN
      2006   Phase 3   NCT00367211   United States
NO ANTI-inflammatory treatment
   Organon and Co
      2009   -   NCT01077843   -
NON-ANTI-TNF biologics
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States
Nsaid
   Jiangsu Province Hospital of TCM
      2019   -   ChiCTR2000034142   China
   Qilu Hospital of Shandong University
      2022   Phase 4   NCT05527444   China
Nsaids
   Janssen Research & Development, LLC
      2015   -   NCT02293681   China
   University Hospital, Bordeaux
      2015   Phase 3   NCT02469753   France;Monaco
Nsaids and sulfasalazine
   Chung Shan Medical University
      2009   Phase 2   NCT02456363   Taiwan
Nsnsaids
   Organon and Co
      2011   -   NCT01327638   -
Observational study
   Janssen Korea, Ltd., Korea
      2007   -   NCT00760669   Korea, Republic of
Olsalazine
   National Center for Research Resources (NCRR)
      1996   Phase 2   NCT00004288   -
Omeprazole
   POZEN
      2006   Phase 3   NCT00367211   United States
Orencia
   Charité University Medicine
      2007   -   EUCTR2007-002967-28-DE   Germany
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
Originator
   Opal Rheumatology Ltd.
      2018   -   NCT03470688   Australia
Originator (legacy) drug
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2018   -   NCT03729674   Canada
Other COX-2 inhibitor
   Organon and Co
      2011   -   NCT01327638   -
Other COX-2 inhibitors
   Organon and Co
      2009   -   NCT01077843   -
Other NON-selective nsaids
   Organon and Co
      2009   -   NCT01077843   -
Oxygen
   Shenzhen Second People's Hospital
      2021   -   ChiCTR2100042477   China
Pamidronate
   Bnai Zion Medical Center
      2014   Phase 4   NCT02313727   Israel
Parecoxib
   Peking Union Medical College Hospital
      2014   -   ChiCTR1800014846   China
Part I - etoricoxib 60 MG
   Organon and Co
      2010   Phase 3   NCT01208207   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
Part I - etoricoxib 90 MG
   Organon and Co
      2010   Phase 3   NCT01208207   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
Part I- naproxen 1000 MG
   Organon and Co
      2010   Phase 3   NCT01208207   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
Part II- etoricoxib 60 MG
   Organon and Co
      2010   Phase 3   NCT01208207   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
Part II- etoricoxib 90 MG
   Organon and Co
      2010   Phase 3   NCT01208207   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
Part II- naproxen 1000 MG
   Organon and Co
      2010   Phase 3   NCT01208207   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
Partial enteral nutrition
   NHS Greater Glasgow and Clyde
      2024   -   NCT06460805   United Kingdom
PPT
   Wang Min
      2024   -   ChiCTR2400093050   China
PRE-filled syringe
   Boehringer Ingelheim
      2014   Phase 2   EUCTR2013-003666-13-IT   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   Boehringer Ingelheim España, S.A.
      2013   Phase 2   EUCTR2013-003666-13-ES   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   Boehringer Ingelheim Finland Ky
      2013   Phase 2   EUCTR2013-003666-13-FI   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2014   Phase 2   EUCTR2013-003666-13-DE   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   Boehringer-Ingelheim bv
      2014   Phase 2   EUCTR2013-003666-13-NL   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   CHRU de TOURS
      2013   Phase 4   EUCTR2012-004939-23-FR   France
   Charité Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2011-000844-56-DE   Germany
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Eli Lilly & Company
      2013   -   EUCTR2011-002325-22-HU   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002325-22-GB   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   -   EUCTR2011-002325-22-ES   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   -   EUCTR2011-002325-22-DE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
      2013   Phase 3   EUCTR2011-002325-22-BE   Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-NL   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Novartis Farma SpA
      2013   Phase 3   EUCTR2013-001089-40-IT   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2017   Phase 3   EUCTR2017-000679-10-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001090-24-ES   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-ES   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
   Novartis Pharma AG
      2021   Phase 4   EUCTR2020-004284-98-GR   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;United States
      2021   Phase 4   EUCTR2020-004284-98-BG   Belgium;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      2019   Phase 3   EUCTR2017-000679-10-GR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-SK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-NL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-CZ   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-GB   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-FI   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      -   Phase 4   EUCTR2020-004284-98-PL   Belgium;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      -   Phase 4   EUCTR2020-004284-98-CZ   Brazil;Bulgaria;China;Colombia;Czech Republic;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Turkey;United States
   Novartis Pharma GmbH
      2016   Phase 4   EUCTR2015-004575-74-DE   Germany
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2015-005021-39-GB   China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom
      2016   Phase 3   EUCTR2015-005021-39-CZ   China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom
      2015   Phase 3   EUCTR2013-005575-41-SK   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-PL   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-NO   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-NL   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-GR   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-FI   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-DK   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-PT   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-NO   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-GR   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-GB   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-DE   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-BE   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001089-40-BG   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001089-40-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001090-24-CZ   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-NL   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-GB   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-NL   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-GB   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-FI   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-DE   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
   SCS Boehringer Ingelheim Comm.V
      2014   Phase 2   EUCTR2013-003666-13-BE   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
   SUN Pharmaceuticals Global FZE
      2017   Phase 2   EUCTR2016-003936-19-HU   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003936-19-ES   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland
   Samsung Bioepis Co., Ltd.
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
   Sun Pharma Global FZE
      2018   Phase 3   EUCTR2018-001060-35-ES   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States
   Sun Pharmaceutical Industries Limited (SPIL)
      2018   Phase 3   EUCTR2018-001060-35-HU   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States
   UCB Biopharma SPRL
      2019   Phase 3   EUCTR2017-003065-95-FR   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-ES   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000957-37-NL   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-GR   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-DE   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-CZ   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
   UCB Biopharma SRL
      2020   Phase 3   EUCTR2019-004163-47-HU   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-GB   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-DE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-CZ   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-BG   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-BE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Türkiye;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-NL   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-HU   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-GB   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-DE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-CZ   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-BG   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-BE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
   UCB Biosciences Inc.
      2014   Phase 1   EUCTR2013-003812-30-NL   France;Germany;Netherlands;Switzerland;United States
Prednisolone
   Charite University, Berlin, Germany
      2002   Phase 2/Phase 3   NCT00244166   Germany
Probiotic group
   Camilo Jose Cela University
      2023   -   NCT05666115   Spain
Propanoic acid
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2013   -   EUCTR2010-019872-65-LT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-SK   Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom
      2011   Phase 3   EUCTR2010-019872-65-CZ   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   Phase 3   EUCTR2010-019872-65-BE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2011   -   EUCTR2010-019872-65-AT   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-HU   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-FI   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      2010   -   EUCTR2010-019872-65-EE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
      -   -   EUCTR2010-019872-65-DE   Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States
Rebamipide
   Korea Otsuka Pharmaceutical Co.,Ltd.
      2007   Phase 3   NCT00576706   Korea, Republic of
   Seoul National University Boramae Hospital
      2021   Phase 4   NCT04885751   -
Recombinant human monoclonal antibody TO IL-17 OF THE IGG1-K-class
   Novartis Pharma Services AG
      2010   -   EUCTR2009-011591-30-NL   Germany;Netherlands;United Kingdom;United States
      2010   Phase 2   EUCTR2009-011591-30-GB   Germany;Netherlands;United Kingdom
      2010   -   EUCTR2009-011591-30-DE   Germany;Netherlands;United Kingdom
      2009   -   EUCTR2008-002631-33-NL   Germany;Netherlands;United Kingdom
      2009   -   EUCTR2008-002631-33-GB   Germany;Netherlands;United Kingdom
      2008   -   EUCTR2008-002631-33-DE   Germany;Netherlands;United Kingdom
Recombinant TNF-A receptor: IGG FC fusion protein
   Zhejiang Hisun Pharmaceutical Co. Ltd.
      2018   -   NCT03636984   -
Remicade
   Biocad
      2016   Phase 3   NCT02762812   Russian Federation
      2015   Phase 1   NCT02359903   Belarus;Russian Federation
   CHRU-TOURS
      2007   -   EUCTR2006-005157-29-FR   France
   Merck Sharp & Dohme Corp.
      2005   Phase 4   NCT00778869   -
      2004   Phase 4   NCT00779935   -
   READE
      2015   Phase 4   EUCTR2015-002284-42-FI   Finland
   Rheumazentrum Ruhrgebiet.
      2006   -   EUCTR2005-002460-29-FI   Belgium;Finland;Germany;United Kingdom
      2006   Phase 4   EUCTR2005-002460-29-BE   Belgium;Finland;Germany;United Kingdom
      2005   Phase 4   EUCTR2005-002460-29-GB   Belgium;Finland;Germany;United Kingdom
      2005   -   EUCTR2005-002460-29-DE   Belgium;Finland;Germany;United Kingdom
   Schering-Plough France
      2008   -   EUCTR2006-001579-40-DK   Denmark;France;Hungary;Spain
      2007   Phase 4   EUCTR2006-001579-40-HU   Denmark;France;Hungary;Spain
      2007   Phase 4   EUCTR2006-001579-40-FR   Denmark;France;Hungary;Spain
      2007   -   EUCTR2006-001579-40-ES   Denmark;France;Hungary;Spain
Remicade 100 MG polvo para concentrado para solucióN para perfusióN
   Schering Plough, S.A
      2010   -   EUCTR2009-016587-36-ES   Spain
Remicade 100 MG pulver TIL konsentrat TIL infusjonsvæSKE, oppløsning
   Diakonhjemmet Hospital AS
      2014   Phase 4   EUCTR2014-002056-40-NO   Norway
Remsima
   UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
      2016   Phase 4   EUCTR2016-002061-54-IT   Italy
Remsima 100 MG pulver TIL konsentrat TIL infusjonsvæSKE, oppløsning
   Diakonhjemmet Hospital AS
      2014   Phase 4   EUCTR2014-002056-40-NO   Norway
Remsima IV
   Celltrion
      2023   -   NCT05866614   France
Remsima SC
   Celltrion
      2023   -   NCT05866614   France
Rhutnfr:FC
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2007   -   EUCTR2006-001061-42-FI   Denmark;Finland;Sweden;United Kingdom
      2006   -   EUCTR2006-001061-42-SE   Denmark;Finland;Sweden;United Kingdom
      2006   Phase 4   EUCTR2006-001061-42-GB   Denmark;Finland;Sweden;United Kingdom
      2006   -   EUCTR2006-001061-42-DK   Denmark;Finland;Sweden;United Kingdom
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
Rinvoq
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 3   EUCTR2019-003229-12-SK   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Risankizumab
   AbbVie
      2014   Phase 2   NCT02047110   Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States
Rituximab
   Charite University, Berlin, Germany
      2007   Phase 2/Phase 3   NCT00432653   Germany
Rituximab/ mabthera
   Charité Universitaetsmedizin
      2006   -   EUCTR2006-002306-64-DE   Germany
Rivaroxaban
   Department of Orthopedics, the First Affliated Hospital of Xinjiang Medical University
      2024   Phase 4   ChiCTR2400092488   China
RO 487-533/F01
   F. Hoffmann-La Roche Ltd.
      2011   Phase 3   EUCTR2009-017488-40-BE   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-SK   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-017488-40-GB   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-DK   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-DE   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-CZ   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-BG   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
RO 487-5733/F01
   F. Hoffmann-La Roche Ltd.
      2011   -   EUCTR2009-017443-34-DE   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2011   -   EUCTR2009-017443-34-BG   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2011   Phase 2;Phase 3   EUCTR2009-017443-34-BE   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-SK   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   Phase 2;Phase 3   EUCTR2009-017443-34-GB   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-CZ   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
RO 487-7533/F01
   F. Hoffmann-La Roche Ltd.
      2010   -   EUCTR2009-017488-40-LT   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-LT   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
RO45-2294
   Charité Universitaetsmedizin
      2006   -   EUCTR2006-002306-64-DE   Germany
Roactemra
   F. Hoffmann-La Roche Ltd.
      2011   Phase 3   EUCTR2009-017488-40-BE   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2011   -   EUCTR2009-017443-34-DE   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2011   -   EUCTR2009-017443-34-BG   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2011   Phase 2;Phase 3   EUCTR2009-017443-34-BE   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-SK   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-LT   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-IT   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-017488-40-GB   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-DK   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-DE   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-CZ   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-BG   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-SK   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-LT   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-IT   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   Phase 2;Phase 3   EUCTR2009-017443-34-GB   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-CZ   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
Roactemra 20 MG/ML, concentrado para solucióN para perfusióN
   F. Hoffmann-La Roche Ltd.
      2010   Phase 3   EUCTR2009-017488-40-ES   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-ES   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
Rosuvastatin
   Diakonhjemmet Hospital
      2013   -   NCT01389388   Norway
RTNV148B IGG
   Centocor BV
      2006   Phase 3   EUCTR2004-003299-12-GB   Belgium;Finland;Germany;United Kingdom
      2006   Phase 3   EUCTR2004-003299-12-BE   Belgium;Finland;Germany;United Kingdom
   Janssen Biologics B.V.
      2006   -   EUCTR2004-003299-12-FI   Belgium;Finland;Germany;United Kingdom
      2006   -   EUCTR2004-003299-12-DE   Belgium;Finland;Germany;United Kingdom
Salazopyrin EN-tabs
   WYETH LEDERLE
      2006   -   EUCTR2005-001549-41-IT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
Salicylazosulfapyridine
   Sun Yat-sen Memorial Hospital of Sun Yat-sen University
      2011   Phase 1+Phase 2   ChiCTR-TRC-11001417   China
Saline
   Peking Union Medical College Hospital
      2014   -   ChiCTR1800014846   China
SAR153191
   Sanofi-aventis Recherche & Développement
      2010   -   EUCTR2009-016068-35-NL   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain
      2010   -   EUCTR2009-016068-35-LT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain
      2010   Phase 2   EUCTR2009-016068-35-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain
      2010   Phase 2   EUCTR2009-016068-35-FR   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain
      2010   -   EUCTR2009-016068-35-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain
      2010   -   EUCTR2009-016068-35-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain
      2010   -   EUCTR2009-016068-35-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain
      2010   -   EUCTR2009-016068-35-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain
      2010   -   EUCTR2009-016068-35-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain
   sanofi-aventis Recherche & Développement
      2010   -   EUCTR2010-019263-11-LT   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain
      2010   -   EUCTR2010-019263-11-HU   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain
      2010   Phase 3   EUCTR2010-019263-11-FR   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain
      2010   Phase 3   EUCTR2010-019263-11-ES   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain
      2010   -   EUCTR2010-019263-11-CZ   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain
      2010   Phase 3   EUCTR2010-019263-11-BE   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain
      2010   -   EUCTR2010-019263-11-AT   Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain
Sarilumab
   Sanofi
      2010   Phase 2   NCT01118728   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Lithuania;Netherlands;Poland;Spain;United States
      2010   Phase 2   NCT01061723   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Lithuania;Netherlands;Poland;Spain;Turkey;United States
SB4
   Samsung Bioepis Co., Ltd.
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
SB5
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland
   Samsung Bioepis Co., Ltd.
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom
Secukinumab
   Afdeling for Rygkirurgi, Led- og Bindevævssygdomme ; Rigshospitalet - Glostrup
      2018   Phase 4   EUCTR2017-004037-93-DK   Denmark
   NOVARTIS FARMA
      2012   Phase 3   EUCTR2012-000046-35-IT   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2011   -   EUCTR2010-024529-18-IT   Belgium;Bulgaria;Canada;Germany;Italy;Mexico;Peru;Russian Federation;Taiwan;Turkey;United Kingdom
   NOVARTIS FARMA S.P.A.
      2015   Phase 3   EUCTR2013-005575-41-IT   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;United Kingdom
   Novartis Farma SpA
      2013   Phase 3   EUCTR2013-001089-40-IT   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2017   Phase 3   EUCTR2017-000679-10-ES   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-ES   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001090-24-ES   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-ES   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
   Novartis Pharma AG
      2021   Phase 4   EUCTR2020-004284-98-GR   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;United States
      2021   Phase 4   EUCTR2020-004284-98-BG   Belgium;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-SE   Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-IT   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-GR   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-CZ   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-BG   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2020   Phase 3   EUCTR2019-001177-90-BE   Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2019   Phase 3   EUCTR2017-000679-10-GR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-SK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PT   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-PL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-NL   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-FR   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States
      2018   Phase 3   EUCTR2017-000679-10-CZ   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-GB   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-FI   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DK   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      2017   Phase 3   EUCTR2017-000679-10-DE   Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States
      -   Phase 4   EUCTR2020-004284-98-PL   Belgium;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Turkey;United States
      -   Phase 4   EUCTR2020-004284-98-CZ   Brazil;Bulgaria;China;Colombia;Czech Republic;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Turkey;United States
   Novartis Pharma GmbH
      2016   Phase 4   EUCTR2015-004575-74-DE   Germany
   Novartis Pharma K.K.
      2018   Phase 3   JPRN-jRCT2080224045   Africa;Asia except Japan;Europe;Japan;North America;Oceania;South America
      2016   Phase 3   JPRN-jRCT2080223186   -
   Novartis Pharma Services AG
      2016   Phase 3   EUCTR2015-005021-39-GB   China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom
      2016   Phase 3   EUCTR2015-005021-39-CZ   China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom
      2015   Phase 3   EUCTR2013-005575-41-SK   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-PL   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-NO   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-NL   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-GR   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-GB   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-FI   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-DK   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-DE   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-CZ   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-BG   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2013-005575-41-AT   Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-PT   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-NO   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-GR   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-GB   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-DE   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001090-24-BE   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2013-001089-40-BG   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001090-24-CZ   Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-NL   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-GB   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2013   Phase 3   EUCTR2013-001089-40-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-NL   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-GB   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-FI   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2012-000046-35-DE   Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2011   -   EUCTR2010-024529-18-GB   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-024529-18-DE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-024529-18-BG   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-024529-18-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2025   -   NCT06905288   Korea, Republic of
      2022   -   NCT05155098   Thailand
      2019   Phase 3   NCT04156620   Belgium;Brazil;Bulgaria;Colombia;Czechia;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States
      2016   Phase 3   NCT02896127   China;Czech Republic;Czechia;Korea, Republic of;United Kingdom
      2016   Phase 4   NCT02763046   Germany
      2016   Phase 3   NCT02750592   Japan
      2015   Phase 3   NCT02159053   Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States
      2014   Phase 3   NCT02008916   Belgium;Czech Republic;Czechia;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States
      2013   Phase 3   NCT01863732   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
      2012   Phase 3   NCT01649375   Austria;Canada;Czech Republic;Czechia;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States
      2011   Phase 3   NCT01358175   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
   Professor Mikkel Østergaard
      2019   Phase 4   NCT03639740   Denmark
   The Affiliated Hospital Of Guizhou Medical University
      2025   Phase 4   NCT06833112   China
   Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
      2024   Phase 1   ChiCTR2400088487   China
      2023   Phase 4   ChiCTR2300071073   China
Secukinumab 150 MG/1 ML solution FOR injection
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-001089-40-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
Secukinumab 150 MG/ML
   Qilu Hospital of Shandong University
      2022   Phase 4   NCT05527444   China
Secukinumab 75 MG/0.5 ML solution FOR injection
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-001089-40-BE   Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States
SHR-1314
   Suzhou Suncadia Biopharmaceuticals Co., Ltd.
      2021   Phase 2/Phase 3   NCT04840485   China
SHR0302
   Jiangsu HengRui Medicine Co., Ltd.
      2020   Phase 2/Phase 3   NCT04481139   China
Simponi
   Charite Universitaetsmedizin
      2016   Phase 4   EUCTR2016-000615-33-DE   Germany
   Chinese University of Hong Kong
      2010   Phase 4   NCT01212653   China
   MD, PhD Salome Kristensen
      2017   Phase 4   EUCTR2017-001970-41-DK   Denmark
   MERCK SHARP & DOHME B.V.
      2012   Phase 4   EUCTR2012-002458-21-NL   Netherlands
   Merck Sharp & Dohme Corp.
      2010   -   NCT01313858   Germany
   READE
      2015   Phase 4   EUCTR2015-002284-42-FI   Finland
SSZ
   Wyeth is now a wholly owned subsidiary of Pfizer
      2005   Phase 4   NCT00247962   Australia;Austria;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Qatar;Saudi Arabia;Spain;Sweden;Switzerland;United Kingdom
Stelara
   Charité Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2011-000844-56-DE   Germany
Sulfasalazine
   Nanchang Hongdu Hospital of TCM
      2020   -   ChiCTR2000038277   China
   Nanfang Hospital of Southern Medical University
      2019   Phase 4   NCT04077957   China
   School of Chinese Medicine Southern Medical University
      2010   -   ChiCTR-TRC-11001274   China
   Sun Yat-sen University
      2008   Phase 2/Phase 3   NCT00889694   -
   WYETH LEDERLE
      2006   -   EUCTR2005-001549-41-IT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
   Zhejiang University of Traditional Chinese Medicine
      2021   -   ChiCTR2100048756   China
   Zhixiang Huang
      2016   Phase 4   NCT02638896   -
Sulfasalazine, SSZ
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
Sulphasalazine
   Wyeth is now a wholly owned subsidiary of Pfizer
      2005   Phase 4   NCT00247962   Australia;Austria;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Qatar;Saudi Arabia;Spain;Sweden;Switzerland;United Kingdom
Sulphasalazine 500 MG EN-tabs
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
Sunpg1622 I dose
   Sun Pharmaceutical Industries Limited
      2017   Phase 2   NCT02980705   Hungary;Poland;Spain;United States
Systemic NON-biological treatments
   Janssen Biotech, Inc.
      2009   -   NCT01081717   United States
Tapering or discontinuation OF etanercept
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2012   -   NCT03880968   -
Technetium labelled glucosamine
   University of Sydney
      2012   -   NCT01789151   Australia
Terbinafine tablets
   Oregon Health and Science University
      2021   Early Phase 1   NCT05119712   United States
Tgaac94 gene therapy vector
   Targeted Genetics Corporation
      2005   Phase 1/Phase 2   NCT00126724   United States
THA
   Department of Orthopedics, the First Affliated Hospital of Xinjiang Medical University
      2024   Phase 4   ChiCTR2400092488   China
Thalidomide
   Chinese PLA General Hospital
      2010   Phase 1 study   ChiCTR-ONRC-10000858   China
   Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
      2009   -   ChiCTR-ONRC-11001846   -
   The First Affiliated Hospital of Henan University of Chinese Medicine
      2023   -   ChiCTR2300067535   China
Thalidomide 100MG
   Shanghai Pharmaceuticals Holding Co., Ltd
      2013   Phase 2   NCT02201043   China
   The General Hospital of People's Liberation Army
      2013   Phase 2 study   ChiCTR-TRC-13003449   China
Thalidomide 150MG
   Shanghai Pharmaceuticals Holding Co., Ltd
      2013   Phase 2   NCT02201043   China
   The General Hospital of People's Liberation Army
      2013   Phase 2 study   ChiCTR-TRC-13003449   China
Thalidomide pill
   Qilu Hospital of Shandong University
      2022   Phase 4   NCT05527444   China
Tildrakizumab
   SUN Pharmaceuticals Global FZE
      2017   Phase 2   EUCTR2016-003936-19-HU   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003936-19-ES   Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States
Tildrakizumab 100 MG/ML
   Sun Pharma Global FZE
      2018   Phase 3   EUCTR2018-001060-35-ES   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States
   Sun Pharmaceutical Industries Limited (SPIL)
      2018   Phase 3   EUCTR2018-001060-35-HU   Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States
TNF alpha
   Chung Shan Medical University
      2009   Phase 2   NCT02456363   Taiwan
TNF-A antagonists, NON-tnfs, dmard NON-biologics
   Biologics & Biosimilars Collective Intelligence Consortium
      2012   -   NCT02922192   -
TNF-alpha antagonists
   Assistance Publique - Hôpitaux de Paris
      2004   -   NCT00224562   France
TNF-inhibition
   Region Skane
      2019   -   NCT03839862   Sweden
Tnfr:FC
   Samsung Bioepis Co., Ltd.
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2007   -   EUCTR2006-001061-42-FI   Denmark;Finland;Sweden;United Kingdom
      2006   -   EUCTR2006-001061-42-SE   Denmark;Finland;Sweden;United Kingdom
      2006   Phase 4   EUCTR2006-001061-42-GB   Denmark;Finland;Sweden;United Kingdom
      2006   -   EUCTR2006-001061-42-DK   Denmark;Finland;Sweden;United Kingdom
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
TNR-001
   Wyeth Pharmaceuticals France, Wyeth Research Division
      2007   -   EUCTR2006-001061-42-FI   Denmark;Finland;Sweden;United Kingdom
      2006   -   EUCTR2006-001061-42-SE   Denmark;Finland;Sweden;United Kingdom
      2006   Phase 4   EUCTR2006-001061-42-GB   Denmark;Finland;Sweden;United Kingdom
      2006   -   EUCTR2006-001061-42-DK   Denmark;Finland;Sweden;United Kingdom
   Wyeth Research Division of Wyeth Pharmaceuticals Inc
      2006   -   EUCTR2005-001549-41-SE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-PT   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-001549-41-IE   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GR   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3;Phase 4   EUCTR2005-001549-41-GB   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-FI   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DK   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-DE   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-001549-41-CZ   Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-HU   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   Phase 3;Phase 4   EUCTR2005-001549-41-ES   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-001549-41-AT   Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom
TNR-001, tnfr:FC
   Wyeth Farma S.A.
      2006   Phase 4   EUCTR2006-002349-35-ES   Spain
Tocilizumab
   F. Hoffmann-La Roche Ltd.
      2011   Phase 3   EUCTR2009-017488-40-BE   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2011   -   EUCTR2009-017443-34-DE   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2011   -   EUCTR2009-017443-34-BG   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2011   Phase 2;Phase 3   EUCTR2009-017443-34-BE   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-SK   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-LT   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-IT   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-017488-40-GB   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   Phase 3   EUCTR2009-017488-40-ES   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-DK   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-DE   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-CZ   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017488-40-BG   Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-SK   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-LT   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-IT   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   Phase 2;Phase 3   EUCTR2009-017443-34-GB   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-ES   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
      2010   -   EUCTR2009-017443-34-CZ   Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom
   Hoffmann-La Roche
      2010   Phase 3   NCT01209702   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;India;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States
      2010   Phase 3   NCT01209689   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;India;Italy;Lithuania;Netherlands;Poland;Slovakia;South Africa;Spain;United Kingdom;United States
Tofacitinib
   Pfizer
      2018   Phase 3   NCT03502616   Australia;Bulgaria;Canada;China;Czechia;France;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States
Tofacitinib 10 MG
   Pfizer
      2013   Phase 2   NCT01786668   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States
Tofacitinib 2 MG
   Pfizer
      2013   Phase 2   NCT01786668   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States
Tofacitinib 5 MG
   Pfizer
      2013   Phase 2   NCT01786668   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States
   Pfizer Inc.
      2018   Phase 3   EUCTR2018-000226-58-CZ   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 3   EUCTR2018-000226-58-HU   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-GB   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-FR   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-ES   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-DE   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-BG   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-AT   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Tofacitinib citrate
   Pfizer Inc, 235 East 42nd Street, New York 10017
      2013   -   EUCTR2011-005689-39-HU   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States
   Pfizer Inc.
      2018   Phase 3   EUCTR2018-000226-58-CZ   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc. 235 East 42nd Street, New York, 10017
      2014   Phase 2   EUCTR2011-005689-39-SK   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States
      2014   Phase 2   EUCTR2011-005689-39-NL   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States
      2014   -   EUCTR2011-005689-39-DE   Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States
      2013   Phase 2   EUCTR2011-005689-39-ES   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States
      2013   -   EUCTR2011-005689-39-CZ   Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 3   EUCTR2018-000226-58-HU   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-GB   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-FR   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-ES   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-DE   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-BG   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-AT   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Tofacitinib citrate tablets
   Jiangsu vcare pharmaceutical technology co., LTD
      2023   Phase 2   NCT05814939   China
Tofacitinib XR
   Pfizer
      2022   -   NCT04876781   Korea, Republic of
Total glucosides paeony capsules
   Sun Yat-sen University
      2011   Phase 4   NCT01517620   China
Tramadol /acetaminophen
   Johnson & Johnson Taiwan Ltd
      2008   Phase 4   NCT00766402   -
Tripterygium
   Jiangsu Provincial Hospital of Traditional Chinese Medicine
      2011   -   ChiCTR-TRC-11001193   China
   Sun Yat-sen University
      2008   Phase 2/Phase 3   NCT00889694   -
UCB4940
   UCB BIOPHARMA SRL
      2018   Phase 2   EUCTR2017-001002-15-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States
   UCB BIOSCIENCES GmbH
      2017   Phase 2   EUCTR2017-001002-15-HU   Hungary
   UCB Biopharma SPRL
      2019   Phase 3   EUCTR2017-003065-95-FR   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-ES   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2018   Phase 2   EUCTR2017-000957-37-NL   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-001002-15-ES   Germany;Hungary;Spain
      2017   Phase 2   EUCTR2017-000957-37-GR   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-DE   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2017-000957-37-CZ   Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States
      2017   Phase 2   EUCTR2016-001102-42-GB   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001102-42-DE   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2017   Phase 2   EUCTR2016-001102-42-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2016   Phase 2   EUCTR2016-001102-42-HU   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2016-001102-42-ES   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States
      2016   Phase 2   EUCTR2016-001102-42-CZ   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
   UCB Biopharma SRL
      2020   Phase 3   EUCTR2019-004163-47-HU   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-GB   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-DE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-CZ   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-BG   Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004163-47-BE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Türkiye;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-NL   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-HU   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-GB   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-DE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-CZ   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-BG   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2017-003065-95-BE   Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2017   Phase 2   EUCTR2017-001002-15-CZ   Bulgaria;Czech Republic;Germany;Hungary;Spain
      2017   Phase 2   EUCTR2017-001002-15-BG   Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States
   UCB Japan Co., Ltd
      2019   Phase 3   JPRN-jRCT2080224781   Asia except Japan;Japan;North America
   UCB Japan Co., Ltd.
      2020   Phase 3   JPRN-jRCT2080225318   Asia except Japan;Europe;Japan;North America
Ultracet
   Chung Shan Medical University
      2008   Phase 4   NCT00647517   Taiwan
Ultrasonographic assessment OF cervical multifidus and longus colli muscle thickness, postural balance and limit OF stability using THE balance platform,cervical flexion and extension strength
   Istanbul Physical Medicine Rehabilitation Training and Research Hospital
      2025   -   NCT06967883   Turkey
Upadacitinib
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2019-003229-12-IT   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Ukraine;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   AbbVie
      2017   Phase 2   NCT03178487   Australia;Belgium;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
   AbbVie Deutschland GmbH & Co. KG
      2020   Phase 3   EUCTR2019-003229-12-SK   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-HU   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-GB   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-FR   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-ES   Argentina;Australia;Brazil;Canada;China;Hungary;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-DE   Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003229-12-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-SE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-NL   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-HR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-000431-14-DE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-PT   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-PL   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-HU   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-GB   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-FR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-FI   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-ES   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-DK   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-CZ   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2017-000431-14-BE   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States
Ustekinumab
   Charite University, Berlin, Germany
      2011   Phase 2   NCT01330901   Germany
   Charité Universitätsmedizin Berlin
      2011   Phase 2   EUCTR2011-000844-56-DE   Germany
Vaccine
   Tel-Aviv Sourasky Medical Center
      2009   Phase 2   NCT01006681   -
VC005 tablets
   Jiangsu vcare pharmaceutical technology co., LTD
      2023   Phase 2   NCT05814939   China
Voltaren resinat
   Charité - Campus Mitte
      2008   Phase 4   EUCTR2007-007637-39-DE   Germany
Xeljanz
   Pfizer Inc.
      2018   Phase 3   EUCTR2018-000226-58-CZ   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2018   Phase 3   EUCTR2018-000226-58-HU   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-FR   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000226-58-ES   Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
Yisaipu
   Nanfang Hospital of Southern Medical University
      2017   Phase 4   NCT03411798   China
   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
      2014   Phase 3   NCT04345458   China
Yuxuebi tablet
   China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
      2021   Phase 4   NCT04934059   China